- Home
- TPVG vs TNGX Comparison
TPVG vs TNGX Comparison
Compare TPVG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- TNGX
- Stock Information
- Founded
- TPVG 2013
- TNGX 2014
- Country
- TPVG United States
- TNGX United States
- Employees
- TPVG N/A
- TNGX N/A
- Industry
- TPVG Other Consumer Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- TNGX Health Care
- Exchange
- TPVG Nasdaq
- TNGX Nasdaq
- Market Cap
- TPVG 253.9M
- TNGX 351.2M
- IPO Year
- TPVG N/A
- TNGX N/A
- Fundamental
- Price
- TPVG $7.16
- TNGX $6.01
- Analyst Decision
- TPVG Hold
- TNGX Strong Buy
- Analyst Count
- TPVG 6
- TNGX 6
- Target Price
- TPVG $6.55
- TNGX $12.20
- AVG Volume (30 Days)
- TPVG 276.3K
- TNGX 2.7M
- Earning Date
- TPVG 08-06-2025
- TNGX 08-06-2025
- Dividend Yield
- TPVG 16.78%
- TNGX N/A
- EPS Growth
- TPVG N/A
- TNGX N/A
- EPS
- TPVG 0.93
- TNGX N/A
- Revenue
- TPVG $101,260,000.00
- TNGX $40,990,000.00
- Revenue This Year
- TPVG N/A
- TNGX N/A
- Revenue Next Year
- TPVG $6.30
- TNGX N/A
- P/E Ratio
- TPVG $7.73
- TNGX N/A
- Revenue Growth
- TPVG N/A
- TNGX 10.09
- 52 Week Low
- TPVG $5.53
- TNGX $1.03
- 52 Week High
- TPVG $9.17
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- TPVG 57.54
- TNGX 76.36
- Support Level
- TPVG $6.93
- TNGX $5.34
- Resistance Level
- TPVG $7.30
- TNGX $6.40
- Average True Range (ATR)
- TPVG 0.16
- TNGX 0.50
- MACD
- TPVG 0.02
- TNGX -0.02
- Stochastic Oscillator
- TPVG 81.51
- TNGX 84.08
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.